Outcomes* · adults and children with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Unscheduled physician visits 44 weeks · adults and children with chronic asthma
Increased showed no clear difference in unscheduled physician visits 44 weeks compared with stable doses of inhaled corticosteroids (low certainty).
1 finding from 1 review
Unscheduled acute care, ED visit, or hospital admission 47 weeks · adults and children with chronic asthma
1 finding from 1 review
Serious adverse events 48 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes serious adverse events 48 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Non‐serious adverse events 43 weeks · adults and children with chronic asthma
It is very uncertain whether increased changes non‐serious adverse events 43 weeks compared with stable doses of inhaled corticosteroids (very low certainty).
1 finding from 1 review
Duration of exacerbation ‐ time to symptom recovery and lung function recovery 52 weeks · adults and children with chronic asthma
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether tripterygium polyglycoside changes improvement in disability grade Defined as achievement of a… compared with corticosteroids (very low certainty).
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age among all randomised compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Death or BPD (28 days) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
BPD at 28 days · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Intraocular inflammation measured by anterior chamber cell and flare 1 week · people who received phacoemulsification
1 finding from 1 review
Intraocular inflammation measured by proportion of participants with corneal edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs showed no clear difference in intraocular inflammation measured by proportion of participants with… compared with corticosteroids (low certainty).
1 finding from 1 review
Proportion of participants with best‐corrected visual acuity of 20/40 1 week · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found